Kidney Cancer, Version 2.2024 Featured Updates to the NCCN Guidelines

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Hilary Bagshaw, Michael Baine, Kathryn Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Andrew Gunn, Naomi Haas, Michael Johnson, Payal Kapur, Jennifer KingChristos Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon Manley, M. Dror Michaelson, Amir Mortazavi, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey Sosman, Randy Sweis, Matthew Zibelman, Ryan Schonfeld, Mary Elizabeth Stein, Lisa A. Gurski

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic therapy options for patients with advanced RCC and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Kidney Cancer.

Original languageEnglish
Pages (from-to)4-16
Number of pages13
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume22
Issue number1
DOIs
StatePublished - Feb 2024

Keywords

  • Carcinoma, Renal Cell/diagnosis
  • Humans
  • Kidney Neoplasms/diagnosis

Fingerprint

Dive into the research topics of 'Kidney Cancer, Version 2.2024 Featured Updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this